Fatigue in chronic liver disease: New insights and therapeutic approaches
The management of fatigue associated with chronic liver disease is a complex and major clinical challenge. Although fatigue can complicate many chronic diseases, it is particularly common in diseases with an inflammatory component. Fatigue can have both peripheral (i.e., neuromuscular) and central (...
Gespeichert in:
Veröffentlicht in: | Liver international 2019-01, Vol.39 (1), p.6-19 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 19 |
---|---|
container_issue | 1 |
container_start_page | 6 |
container_title | Liver international |
container_volume | 39 |
creator | Swain, Mark G. Jones, David E. J. |
description | The management of fatigue associated with chronic liver disease is a complex and major clinical challenge. Although fatigue can complicate many chronic diseases, it is particularly common in diseases with an inflammatory component. Fatigue can have both peripheral (i.e., neuromuscular) and central (i.e., resulting from changes in neurotransmission within the brain) causes. However, fatigue in chronic liver disease has strong social/contextual components and is often associated with behavioural alterations including depression and anxiety. Given the increasing awareness of patient‐reported outcomes as important components of treatment outcomes and clinical research, there is a growing need to better understand and manage this poorly understood yet debilitating symptom. Although several pathophysiological mechanisms for explaining the development of fatigue have been generated, our understanding of fatigue in patients with chronic liver disease remains incomplete. A better understanding of the pathways and neurotransmitter systems involved may provide specific directed therapies. Currently, the management of fatigue in chronic liver disease can involve a combined use of methods to beneficially alter behavioural components and pharmacological interventions, of which several treatments have potential for the improved management of fatigue in chronic liver disease. However, evidence and consensus are lacking on the best approach and the most appropriate biochemical target(s) whilst clinical trials to address this issue have been few and limited by small sample size. In this review, we outline current understanding of the impact of fatigue and related symptoms in chronic liver disease, discuss theories of pathogenesis, and examine current and emerging approaches to its treatment. |
doi_str_mv | 10.1111/liv.13919 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2058504952</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2058504952</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4549-ad821e5b8b17f5a2d3bce0922a653ae60a4487e2ccd6d36ec51eb7302b2ab49f3</originalsourceid><addsrcrecordid>eNp1kE1Lw0AQhhdRbK0e_AMS8KKHtPvZZL1JsVooelGvy2YzabekSd1NLP33rqb2IDiXGZiHZ4YXoUuChyTUqLSfQ8IkkUeoT3iSxowycnyYKeuhM-9XGBMpBTlFPSolEwTzPppNdWMXLUS2iszS1ZU1UdCBi3LrQXu4i55hG7beLpaNj3SVR80SnN5A2wRWbzau1mYJ_hydFLr0cLHvA_Q2fXidPMXzl8fZ5H4eGy64jHWeUgIiSzOSFELTnGUGsKRUjwXTMMaa8zQBakw-ztkYjCCQJQzTjOqMy4IN0E3nDYc_WvCNWltvoCx1BXXrFcUiFZhLQQN6_Qdd1a2rwneKEiEZTwgWgbrtKONq7x0UauPsWrudIlh956tCIOon38Be7Y1ttob8QP4GGoBRB2xtCbv_TWo-e--UX-IZg9o</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2159347105</pqid></control><display><type>article</type><title>Fatigue in chronic liver disease: New insights and therapeutic approaches</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Swain, Mark G. ; Jones, David E. J.</creator><creatorcontrib>Swain, Mark G. ; Jones, David E. J.</creatorcontrib><description>The management of fatigue associated with chronic liver disease is a complex and major clinical challenge. Although fatigue can complicate many chronic diseases, it is particularly common in diseases with an inflammatory component. Fatigue can have both peripheral (i.e., neuromuscular) and central (i.e., resulting from changes in neurotransmission within the brain) causes. However, fatigue in chronic liver disease has strong social/contextual components and is often associated with behavioural alterations including depression and anxiety. Given the increasing awareness of patient‐reported outcomes as important components of treatment outcomes and clinical research, there is a growing need to better understand and manage this poorly understood yet debilitating symptom. Although several pathophysiological mechanisms for explaining the development of fatigue have been generated, our understanding of fatigue in patients with chronic liver disease remains incomplete. A better understanding of the pathways and neurotransmitter systems involved may provide specific directed therapies. Currently, the management of fatigue in chronic liver disease can involve a combined use of methods to beneficially alter behavioural components and pharmacological interventions, of which several treatments have potential for the improved management of fatigue in chronic liver disease. However, evidence and consensus are lacking on the best approach and the most appropriate biochemical target(s) whilst clinical trials to address this issue have been few and limited by small sample size. In this review, we outline current understanding of the impact of fatigue and related symptoms in chronic liver disease, discuss theories of pathogenesis, and examine current and emerging approaches to its treatment.</description><identifier>ISSN: 1478-3223</identifier><identifier>EISSN: 1478-3231</identifier><identifier>DOI: 10.1111/liv.13919</identifier><identifier>PMID: 29935104</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Anxiety ; Brain ; Chronic Disease ; Chronic illnesses ; Clinical trials ; Disease control ; Fatigue ; Fatigue - etiology ; Fatigue - physiopathology ; Fatigue - therapy ; Humans ; Liver ; Liver diseases ; Liver Diseases - complications ; Management ; Medical research ; Mental depression ; Muscular fatigue ; Neurotransmission ; Pathogenesis ; Patients ; Pharmacology ; Quality of Life ; SAMe</subject><ispartof>Liver international, 2019-01, Vol.39 (1), p.6-19</ispartof><rights>2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><rights>2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><rights>2019 John Wiley & Sons A/S</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4549-ad821e5b8b17f5a2d3bce0922a653ae60a4487e2ccd6d36ec51eb7302b2ab49f3</citedby><cites>FETCH-LOGICAL-c4549-ad821e5b8b17f5a2d3bce0922a653ae60a4487e2ccd6d36ec51eb7302b2ab49f3</cites><orcidid>0000-0002-0083-5564</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fliv.13919$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fliv.13919$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,778,782,1414,27907,27908,45557,45558</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29935104$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Swain, Mark G.</creatorcontrib><creatorcontrib>Jones, David E. J.</creatorcontrib><title>Fatigue in chronic liver disease: New insights and therapeutic approaches</title><title>Liver international</title><addtitle>Liver Int</addtitle><description>The management of fatigue associated with chronic liver disease is a complex and major clinical challenge. Although fatigue can complicate many chronic diseases, it is particularly common in diseases with an inflammatory component. Fatigue can have both peripheral (i.e., neuromuscular) and central (i.e., resulting from changes in neurotransmission within the brain) causes. However, fatigue in chronic liver disease has strong social/contextual components and is often associated with behavioural alterations including depression and anxiety. Given the increasing awareness of patient‐reported outcomes as important components of treatment outcomes and clinical research, there is a growing need to better understand and manage this poorly understood yet debilitating symptom. Although several pathophysiological mechanisms for explaining the development of fatigue have been generated, our understanding of fatigue in patients with chronic liver disease remains incomplete. A better understanding of the pathways and neurotransmitter systems involved may provide specific directed therapies. Currently, the management of fatigue in chronic liver disease can involve a combined use of methods to beneficially alter behavioural components and pharmacological interventions, of which several treatments have potential for the improved management of fatigue in chronic liver disease. However, evidence and consensus are lacking on the best approach and the most appropriate biochemical target(s) whilst clinical trials to address this issue have been few and limited by small sample size. In this review, we outline current understanding of the impact of fatigue and related symptoms in chronic liver disease, discuss theories of pathogenesis, and examine current and emerging approaches to its treatment.</description><subject>Anxiety</subject><subject>Brain</subject><subject>Chronic Disease</subject><subject>Chronic illnesses</subject><subject>Clinical trials</subject><subject>Disease control</subject><subject>Fatigue</subject><subject>Fatigue - etiology</subject><subject>Fatigue - physiopathology</subject><subject>Fatigue - therapy</subject><subject>Humans</subject><subject>Liver</subject><subject>Liver diseases</subject><subject>Liver Diseases - complications</subject><subject>Management</subject><subject>Medical research</subject><subject>Mental depression</subject><subject>Muscular fatigue</subject><subject>Neurotransmission</subject><subject>Pathogenesis</subject><subject>Patients</subject><subject>Pharmacology</subject><subject>Quality of Life</subject><subject>SAMe</subject><issn>1478-3223</issn><issn>1478-3231</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kE1Lw0AQhhdRbK0e_AMS8KKHtPvZZL1JsVooelGvy2YzabekSd1NLP33rqb2IDiXGZiHZ4YXoUuChyTUqLSfQ8IkkUeoT3iSxowycnyYKeuhM-9XGBMpBTlFPSolEwTzPppNdWMXLUS2iszS1ZU1UdCBi3LrQXu4i55hG7beLpaNj3SVR80SnN5A2wRWbzau1mYJ_hydFLr0cLHvA_Q2fXidPMXzl8fZ5H4eGy64jHWeUgIiSzOSFELTnGUGsKRUjwXTMMaa8zQBakw-ztkYjCCQJQzTjOqMy4IN0E3nDYc_WvCNWltvoCx1BXXrFcUiFZhLQQN6_Qdd1a2rwneKEiEZTwgWgbrtKONq7x0UauPsWrudIlh956tCIOon38Be7Y1ttob8QP4GGoBRB2xtCbv_TWo-e--UX-IZg9o</recordid><startdate>201901</startdate><enddate>201901</enddate><creator>Swain, Mark G.</creator><creator>Jones, David E. J.</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0083-5564</orcidid></search><sort><creationdate>201901</creationdate><title>Fatigue in chronic liver disease: New insights and therapeutic approaches</title><author>Swain, Mark G. ; Jones, David E. J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4549-ad821e5b8b17f5a2d3bce0922a653ae60a4487e2ccd6d36ec51eb7302b2ab49f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Anxiety</topic><topic>Brain</topic><topic>Chronic Disease</topic><topic>Chronic illnesses</topic><topic>Clinical trials</topic><topic>Disease control</topic><topic>Fatigue</topic><topic>Fatigue - etiology</topic><topic>Fatigue - physiopathology</topic><topic>Fatigue - therapy</topic><topic>Humans</topic><topic>Liver</topic><topic>Liver diseases</topic><topic>Liver Diseases - complications</topic><topic>Management</topic><topic>Medical research</topic><topic>Mental depression</topic><topic>Muscular fatigue</topic><topic>Neurotransmission</topic><topic>Pathogenesis</topic><topic>Patients</topic><topic>Pharmacology</topic><topic>Quality of Life</topic><topic>SAMe</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Swain, Mark G.</creatorcontrib><creatorcontrib>Jones, David E. J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Liver international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Swain, Mark G.</au><au>Jones, David E. J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fatigue in chronic liver disease: New insights and therapeutic approaches</atitle><jtitle>Liver international</jtitle><addtitle>Liver Int</addtitle><date>2019-01</date><risdate>2019</risdate><volume>39</volume><issue>1</issue><spage>6</spage><epage>19</epage><pages>6-19</pages><issn>1478-3223</issn><eissn>1478-3231</eissn><abstract>The management of fatigue associated with chronic liver disease is a complex and major clinical challenge. Although fatigue can complicate many chronic diseases, it is particularly common in diseases with an inflammatory component. Fatigue can have both peripheral (i.e., neuromuscular) and central (i.e., resulting from changes in neurotransmission within the brain) causes. However, fatigue in chronic liver disease has strong social/contextual components and is often associated with behavioural alterations including depression and anxiety. Given the increasing awareness of patient‐reported outcomes as important components of treatment outcomes and clinical research, there is a growing need to better understand and manage this poorly understood yet debilitating symptom. Although several pathophysiological mechanisms for explaining the development of fatigue have been generated, our understanding of fatigue in patients with chronic liver disease remains incomplete. A better understanding of the pathways and neurotransmitter systems involved may provide specific directed therapies. Currently, the management of fatigue in chronic liver disease can involve a combined use of methods to beneficially alter behavioural components and pharmacological interventions, of which several treatments have potential for the improved management of fatigue in chronic liver disease. However, evidence and consensus are lacking on the best approach and the most appropriate biochemical target(s) whilst clinical trials to address this issue have been few and limited by small sample size. In this review, we outline current understanding of the impact of fatigue and related symptoms in chronic liver disease, discuss theories of pathogenesis, and examine current and emerging approaches to its treatment.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>29935104</pmid><doi>10.1111/liv.13919</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0002-0083-5564</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1478-3223 |
ispartof | Liver international, 2019-01, Vol.39 (1), p.6-19 |
issn | 1478-3223 1478-3231 |
language | eng |
recordid | cdi_proquest_miscellaneous_2058504952 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
subjects | Anxiety Brain Chronic Disease Chronic illnesses Clinical trials Disease control Fatigue Fatigue - etiology Fatigue - physiopathology Fatigue - therapy Humans Liver Liver diseases Liver Diseases - complications Management Medical research Mental depression Muscular fatigue Neurotransmission Pathogenesis Patients Pharmacology Quality of Life SAMe |
title | Fatigue in chronic liver disease: New insights and therapeutic approaches |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T03%3A15%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fatigue%20in%20chronic%20liver%20disease:%20New%20insights%20and%20therapeutic%20approaches&rft.jtitle=Liver%20international&rft.au=Swain,%20Mark%20G.&rft.date=2019-01&rft.volume=39&rft.issue=1&rft.spage=6&rft.epage=19&rft.pages=6-19&rft.issn=1478-3223&rft.eissn=1478-3231&rft_id=info:doi/10.1111/liv.13919&rft_dat=%3Cproquest_cross%3E2058504952%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2159347105&rft_id=info:pmid/29935104&rfr_iscdi=true |